{"entity":{"id":"lipid-nanoparticle","kind":"term","name":"Lipid nanoparticles for RNA delivery","aka":["LNP","LNPs","lipid nanoparticle","RNA lipid nanoparticle","mRNA-LNP"],"tldr":"A lipid nanoparticle is a formulated fat-based carrier that protects RNA and helps it enter cells. Getting into a cell, releasing usable RNA into the cell fluid and making protein are separate steps, and a particle can succeed at the first without the others.","summary":"A typical RNA-delivery lipid nanoparticle combines an ionisable lipid, a phospholipid, cholesterol and a polyethylene glycol lipid around the RNA; the proportions, lipid identities and preparation change behaviour, so the label LNP alone does not name a product. Ionisable lipids change charge with pH. In common designs they are more protonated in an acidic environment and less charged at physiological pH; the extent depends on the lipid and its environment. This can support membrane interactions during endosomal escape, whose performance remains formulation- and cell-dependent (Hou and colleagues, review). Cells usually take particles into endosomes, and messenger RNA is translated by ribosomes in the cytosol, so usable delivery needs the RNA to leave the endosome. Ordinary messenger RNA does not need to enter the nucleus.\n\nUptake and expression were measured separately in primary human adipocytes, fibroblasts and HeLa cells with six LNP formulations of similar size (54 to 73 nm) carrying eGFP mRNA: total uptake was necessary but not a sufficient predictor of delivery, one formulation gave the highest eGFP expression despite moderate uptake, prolonged uptake impaired endosomal acidification and left mRNA in compartments unproductive for delivery, and early endocytic and recycling compartments had the highest probability of escape (Paramasivam and colleagues). In that study eGFP expression served as a proxy for release; it did not measure the fraction of RNA that escaped.\n\nWhere particles go depends on formulation and route. In female BALB/c mice given luciferase-mRNA LNPs by intramuscular, subcutaneous or intravenous injection, some intramuscular particles reached the liver and spleen, smaller particles more than larger ones, bigger particles tended to stay at the injection site, and liver expression was the most prominent; exposure and expression were not linearly related (Di and colleagues). Mouse distribution is not another product's distribution in people, and local injection does not establish local delivery. Readouts answer different questions: particle size, RNA integrity and encapsulated fraction describe the product; a labelled lipid or labelled RNA shows where a label went, not that intact RNA arrived or was released; and protein per identified live cell shows expression. In the mouse study a lipid label (DiR or deuterium-labelled cholesterol) and luciferase activity were measured separately and did not track each other linearly, and every figure needs its denominator (all cells, live cells or expressing cells). Uptake and protein are different fractions: in the six-formulation study the formulation with the highest eGFP expression had only moderate uptake, so a formulation that takes up in more cells can still make protein in fewer. Message and effect also run on separate clocks: in cultured mouse T cells CAR expression from LNP mRNA peaked at 24 hours and fell over the next days (Rurik and colleagues), and the same RNA in particles of different size or by a different route distributed differently, so the same RNA is not the same product.\n\nThe cancer relevance is as a carrier of antigen-encoding RNA or of instructions for engineering immune cells. The carrier, where it goes, which cells make protein and what that protein does are different questions; none of these studies is evidence of clinical benefit.","asOf":"2026-11-14","links":[{"label":"Endosomal escape of delivered mRNA from endosomal recycling tubules visualized at the nanoscale.","url":"https://doi.org/10.1083/jcb.202110137"},{"label":"Biodistribution and Non-linear Gene Expression of mRNA LNPs Affected by Delivery Route and Particle Size.","url":"https://doi.org/10.1007/s11095-022-03166-5"},{"label":"Selective organ targeting (SORT) nanoparticles for tissue-specific mRNA delivery and CRISPR-Cas gene editing.","url":"https://doi.org/10.1038/s41565-020-0669-6"},{"label":"Lipid nanoparticles for mRNA delivery.","url":"https://doi.org/10.1038/s41578-021-00358-0"},{"label":"CAR T cells produced in vivo to treat cardiac injury.","url":"https://doi.org/10.1126/science.abm0594"}],"tags":["delivery-vehicle","rna-delivery"],"related":["rna-lipoplex","targeted-lnps"],"cancers":[],"sections":[],"technologies":["mrna-lnp-manufacturing","in-vivo-car-t","neoantigen-mrna-vaccine"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["In an invented comparison using 100 identified live cells per formulation at the same measurement time, A shows uptake in 70 cells and encoded protein in 10; B shows uptake in 40 and protein in 25. Uptake is therefore 70 versus 40 per cent, while protein expression is 10 versus 25 per cent on the same live-cell denominator. These separate counts do not show which cells had both signals, the fraction of intact RNA that escaped, the amount of protein per cell or a biological effect. Name the cargo, cell population, assay, timing and controls before comparing formulations; a brighter carrier signal alone does not establish usable RNA delivery."],"category":"Treatment jargon"},"route":"/terms/lipid-nanoparticle/","neighbours":{"term":[{"id":"rna-lipoplex","kind":"term","name":"RNA-lipoplex","route":"/terms/rna-lipoplex/"},{"id":"targeted-lnps","kind":"term","name":"Targeted lipid nanoparticles","route":"/terms/targeted-lnps/"}],"technology":[{"id":"in-vivo-car-t","kind":"technology","name":"In vivo CAR-T","route":"/technologies/in-vivo-car-t/"},{"id":"mrna-lnp-manufacturing","kind":"technology","name":"mRNA and lipid nanoparticle manufacturing","route":"/technologies/mrna-lnp-manufacturing/"},{"id":"neoantigen-mrna-vaccine","kind":"technology","name":"Personalised neoantigen (mRNA) vaccines","route":"/technologies/neoantigen-mrna-vaccine/"}]}}